Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Penta International Corp
483
•Penta International Corp•February 16, 2024

Penta International Corp – FDA 483, Feb 16, 2024

Record Details

An FDA inspection conducted from February 12-16, 2024, at Penta Manufacturing Company, an API Repacker/Relabeler in West Caldwell, NJ, identified significant deviations from regulatory requirements for Active Pharmaceutical Ingredients (APIs). The firm received an FDA Form 483 detailing eight observations related to quality control and operational practices.

Key issues included the inadequate cleaning and sanitization of shared utensils used for APIs, posing a contamination risk. Certificates of Analysis issued by the company for repacked products lacked essential information about the analyzing laboratory and original manufacturers. Furthermore, Penta Manufacturing failed to perform stability studies for repacked APIs in market-simulating containers and assigned unsupported retest/expiration dates that often exceeded original manufacturer specifications.

Procedural shortcomings were prominent: there was an absence of master production instructions for API products, a lack of documented procedures for a quality unit and its responsibilities (such as product release and complaint resolution), and missing documented procedures for material sampling, testing, and laboratory data management. The firm also lacked specific test methods for liquid APIs and corresponding employee training records. Critically, Penta Manufacturing did not conduct identity testing for each API batch, including specific tests for high-risk products like Glycerin USP, and had no supplier qualification program.

To achieve compliance with API Good Manufacturing Practices, Penta Manufacturing Company must implement comprehensive corrective actions. These actions should include developing robust quality systems, establishing proper cleaning and testing protocols, conducting necessary stability studies, and ensuring thorough documentation and effective quality unit oversight.

Company
Penta International Corp
Inspection date
February 16, 2024
Product type
drugs
Office
New Jersey District Office
People
  • Mark Volpe (company_representative)
  • Helen Verdel (Director of Clinical Training)
View Company Profile

ID · 0237be88-a492-47bd-958f-a9667afe6c96

Other documents for Penta International Corp
  • EIR - 2022-02-10February 10, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Penta International Corp
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.